MX357510B - Metodos para tratar ataques de gota. - Google Patents
Metodos para tratar ataques de gota.Info
- Publication number
- MX357510B MX357510B MX2014005398A MX2014005398A MX357510B MX 357510 B MX357510 B MX 357510B MX 2014005398 A MX2014005398 A MX 2014005398A MX 2014005398 A MX2014005398 A MX 2014005398A MX 357510 B MX357510 B MX 357510B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- reducing agent
- drop attacks
- treat drop
- attacks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059433 WO2013066353A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating gout flares |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005398A MX2014005398A (es) | 2015-04-08 |
| MX357510B true MX357510B (es) | 2018-07-12 |
Family
ID=48192537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005398A MX357510B (es) | 2011-11-04 | 2011-11-04 | Metodos para tratar ataques de gota. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2775836B8 (enExample) |
| JP (1) | JP6008974B2 (enExample) |
| KR (1) | KR101848121B1 (enExample) |
| CN (2) | CN109045009A (enExample) |
| AU (1) | AU2011380510B2 (enExample) |
| BR (1) | BR112014010729A2 (enExample) |
| CA (1) | CA2859693C (enExample) |
| CL (1) | CL2014001157A1 (enExample) |
| DK (1) | DK2775836T3 (enExample) |
| EA (1) | EA201490928A1 (enExample) |
| ES (1) | ES2698396T3 (enExample) |
| IL (1) | IL232384A (enExample) |
| MX (1) | MX357510B (enExample) |
| NZ (1) | NZ624726A (enExample) |
| PH (1) | PH12014500990A1 (enExample) |
| PL (1) | PL2775836T3 (enExample) |
| SG (1) | SG11201401981TA (enExample) |
| WO (1) | WO2013066353A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080009111A (ko) | 2005-04-11 | 2008-01-24 | 새비언트 파마수티컬즈 인크. | 유레이트 옥시다아제의 변이형 및 이의 용도 |
| JP2012531596A (ja) | 2009-06-25 | 2012-12-10 | サヴィエント・ファーマシューティカルズ・インコーポレイテッド | Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット |
| US8918181B2 (en) | 2010-11-16 | 2014-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
| AU2013245675B2 (en) * | 2012-04-13 | 2017-02-09 | Cymabay Therapeutics, Inc. | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| JP7086980B2 (ja) * | 2017-10-26 | 2022-06-20 | 大塚製薬株式会社 | イノシトールリン酸含有組成物 |
| CN109223707B (zh) * | 2018-09-13 | 2020-12-08 | 中国药科大学 | 一种尿酸酶外用凝胶制剂、其制备方法及用途 |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN114028584B (zh) * | 2021-11-18 | 2023-09-05 | 辽宁万嘉医药科技有限公司 | 一种降尿酸的多酚多元环糊精包合物及其制备方法 |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| KR102963966B1 (ko) | 2023-12-05 | 2026-05-11 | 인제대학교 산학협력단 | 알코올 스프레이를 활용한 환자 냉각장치 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US6624194B1 (en) | 1999-06-04 | 2003-09-23 | Metabolex, Inc. | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US8288438B2 (en) * | 2005-03-21 | 2012-10-16 | Metabolex, Inc. | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer |
| BRPI0819847B1 (pt) * | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| MX2010011603A (es) * | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
-
2011
- 2011-11-04 MX MX2014005398A patent/MX357510B/es active IP Right Grant
- 2011-11-04 NZ NZ624726A patent/NZ624726A/en not_active IP Right Cessation
- 2011-11-04 ES ES11875217T patent/ES2698396T3/es active Active
- 2011-11-04 WO PCT/US2011/059433 patent/WO2013066353A1/en not_active Ceased
- 2011-11-04 AU AU2011380510A patent/AU2011380510B2/en not_active Ceased
- 2011-11-04 DK DK11875217.9T patent/DK2775836T3/en active
- 2011-11-04 CN CN201810759998.1A patent/CN109045009A/zh active Pending
- 2011-11-04 EP EP11875217.9A patent/EP2775836B8/en not_active Not-in-force
- 2011-11-04 PL PL11875217T patent/PL2775836T3/pl unknown
- 2011-11-04 KR KR1020147015186A patent/KR101848121B1/ko not_active Expired - Fee Related
- 2011-11-04 EA EA201490928A patent/EA201490928A1/ru unknown
- 2011-11-04 CA CA2859693A patent/CA2859693C/en not_active Expired - Fee Related
- 2011-11-04 SG SG11201401981TA patent/SG11201401981TA/en unknown
- 2011-11-04 BR BR112014010729A patent/BR112014010729A2/pt not_active Application Discontinuation
- 2011-11-04 CN CN201180076190.XA patent/CN104066324A/zh active Pending
- 2011-11-04 JP JP2014541013A patent/JP6008974B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-30 IL IL232384A patent/IL232384A/en active IP Right Grant
- 2014-05-02 CL CL2014001157A patent/CL2014001157A1/es unknown
- 2014-05-02 PH PH12014500990A patent/PH12014500990A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6008974B2 (ja) | 2016-10-19 |
| PL2775836T3 (pl) | 2019-02-28 |
| KR20140121384A (ko) | 2014-10-15 |
| JP2014532760A (ja) | 2014-12-08 |
| EP2775836A4 (en) | 2015-05-20 |
| BR112014010729A2 (pt) | 2018-03-20 |
| DK2775836T3 (en) | 2018-12-03 |
| EP2775836A1 (en) | 2014-09-17 |
| CA2859693C (en) | 2018-05-22 |
| AU2011380510A1 (en) | 2014-05-29 |
| WO2013066353A1 (en) | 2013-05-10 |
| PH12014500990A1 (en) | 2014-08-04 |
| AU2011380510B2 (en) | 2016-05-12 |
| CA2859693A1 (en) | 2013-05-10 |
| NZ624726A (en) | 2016-01-29 |
| EP2775836B1 (en) | 2018-09-12 |
| CN109045009A (zh) | 2018-12-21 |
| CN104066324A (zh) | 2014-09-24 |
| EA201490928A1 (ru) | 2014-11-28 |
| KR101848121B1 (ko) | 2018-04-11 |
| IL232384A0 (en) | 2014-06-30 |
| EP2775836B8 (en) | 2018-10-24 |
| IL232384A (en) | 2017-10-31 |
| CL2014001157A1 (es) | 2015-01-16 |
| MX2014005398A (es) | 2015-04-08 |
| ES2698396T3 (es) | 2019-02-04 |
| SG11201401981TA (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| CO6761389A2 (es) | Inhibidores de nampt y rock | |
| MX394252B (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf | |
| CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
| PH12014500990A1 (en) | Methods for treating gout flares | |
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| BR112014028042A2 (pt) | inibidores de nampt | |
| MX2013008376A (es) | Composiciones y metodos para el tratamiento de cancer. | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| MX2014000515A (es) | Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido. | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| EA202091676A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
| PH12013502199A1 (en) | Microrna compounds and methods for modulating mr-21 activity | |
| UY33461A (es) | Compuestos heterocíclicos, su preparación y su aplicación terapéutica | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| FI20115165A0 (fi) | Terapeuttisia ja diagnostisia menetelmiä | |
| BR112014005864A2 (pt) | compostos de beta-lactama para tratar diabetes | |
| BR112014011315A2 (pt) | agente terapêutico para artrose, e, método para o tratamento da artrose | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |